Current stage -Stage IV Posts on Medivizor
Navigation Menu

Current stage -Stage IV Posts on Medivizor

Quality of life in patients with advanced prostate cancer after apalutamide treatment

Posted by on Jan 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...

Read More

Evaluating the order of hormone therapy drugs for patients with prostate cancer

Posted by on Jan 5, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...

Read More

Abiraterone acetate and prednisone in patients with metastatic, castration‑sensitive prostate cancer

Posted by on Dec 30, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...

Read More

Evaluating the safety of re-treatment with radium-223

Posted by on Sep 16, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...

Read More

Evaluating enzalutamide plus androgen deprivation therapy to treat metastatic prostate cancer

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...

Read More

Searching for patients with metastatic castration resistant prostate cancer to test a targeted therapy option

Posted by on Jun 24, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...

Read More

Searching for patients with prostate cancer to test this new treatment combination

Posted by on Jun 24, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with castration-resistant prostate cancer (CRPC; cancer that progresses after hormonal therapy). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or...

Read More